The TREAT Study: Prevention of Anemia in Diabetic Patients with CKD
(
00:00
/27:22)
Outline
1, The TREAT Study: Preven
2. Conflicts of Interest
3. Decision to Prescribe E
4. Rationale for uality of
5. Adverse effects of tran
6.
7.
8.
9. Definition of Anemia
10. Non Dialysis CKD RCTs
11. Dialysis RCTs
12. Canadian Erythropoieti
13. Dialysis patients: Sev
14. 6 Min Walking Test: Di
15. KD Physical Function S
16. Decision to Prescribe:
17. Randomized Controlled
18.
19. ascular Access (Amgen
20. Can-Europe Study Group
21. Effect of hemoglobin t
22.
23.
24. Trial to Reduce Cardio
25. Design
26. Endpoints
27. Statistical Considerat
28. Enrollment Criteria
29. Patients Enrollment by
30. Baseline Characteristi
31. Baseline Characteristi
32. Baseline Characteristi
33. Patient Follow-up
34. Hemoglobin Levels
35. Cardiovascular Composi
36. Renal Composite: Death
37. All Cause Mortality
38. Fatal and Nonfatal CHF
39. Fatal and Nonfatal MI
40. ESRD
41. Fatal and Nonfatal Str
42. Primary Composite and
43. Fatal and Nonfatal Str
44. Types of Stroke
45. Other ESA-Related Find
46. Malignancy in TREAT
47. Red Cell Transfusions
48. MEASUREMENTS
49. FACT - fatigue
50. Prespecified oL Outcom
51. TREAT 4038
52. Baseline Scores: Presp
53. Prespecified Outcomes:
54. Prespecified Outcomes:
55. Prespecified Outcomes:
56. Change in E-5D
57. Scan
58. Scan
59. Past Randomization Fac
60. Post randomization fac
61. Hyporesponders
62. Conclusions
63. Conclusions: Dialysis:
64. Recommendations
Thumbnails
1, The TREAT Study: Preven
2. Conflicts of Interest
3. Decision to Prescribe E
4. Rationale for uality of
5. Adverse effects of tran
6.
7.
8.
9. Definition of Anemia
10. Non Dialysis CKD RCTs
11. Dialysis RCTs
12. Canadian Erythropoieti
13. Dialysis patients: Sev
14. 6 Min Walking Test: Di
15. KD Physical Function S
16. Decision to Prescribe:
17. Randomized Controlled
18.
19. ascular Access (Amgen
20. Can-Europe Study Group
21. Effect of hemoglobin t
22.
23.
24. Trial to Reduce Cardio
25. Design
26. Endpoints
27. Statistical Considerat
28. Enrollment Criteria
29. Patients Enrollment by
30. Baseline Characteristi
31. Baseline Characteristi
32. Baseline Characteristi
33. Patient Follow-up
34. Hemoglobin Levels
35. Cardiovascular Composi
36. Renal Composite: Death
37. All Cause Mortality
38. Fatal and Nonfatal CHF
39. Fatal and Nonfatal MI
40. ESRD
41. Fatal and Nonfatal Str
42. Primary Composite and
43. Fatal and Nonfatal Str
44. Types of Stroke
45. Other ESA-Related Find
46. Malignancy in TREAT
47. Red Cell Transfusions
48. MEASUREMENTS
49. FACT - fatigue
50. Prespecified oL Outcom
51. TREAT 4038
52. Baseline Scores: Presp
53. Prespecified Outcomes:
54. Prespecified Outcomes:
55. Prespecified Outcomes:
56. Change in E-5D
57. Scan
58. Scan
59. Past Randomization Fac
60. Post randomization fac
61. Hyporesponders
62. Conclusions
63. Conclusions: Dialysis:
64. Recommendations
Notes
MAU: Summary
Time: 01 min 17 sec
Search
Search in
Slide text
Slide notes
Slide titles
References
Slide
01
/64
00:00
/ 27:22
